Fischer Medical Ventures Limited submitted a revised investor and strategic partnership presentation to stock exchanges on September 17, 2026. The filing updates materials from an investor and analyst call held on September 7, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company positions itself as an integrated AI-enabled healthcare platform. Its ecosystem spans medical imaging, population-scale screening, hospital digitization, and analytics. Operations cover India, the US, Hong Kong, MENA, and SEA.

Strategic Ecosystem

Fischer Medical Ventures operates through three core brands. Time Medical provides the technology foundation with advanced MRI and diagnostic equipment. FlynnCare Health Innovations develops AI healthcare applications and the MIDAS screening ecosystem. Fischer Medical Ventures serves as the commercialization and capital vehicle.

Imaging Portfolio

The company’s diagnostic range includes MRI systems from 0.35T to 7.0T. Key products include the PICA and AURA open architecture systems, and the MICA, QUIN, and NEXA closed-bore platforms. The portfolio also features CT scanners, portable X-ray machines, and mammography solutions.

AI and Digital Health

FlynnCare’s MIDAS platform consolidates ten screening modules including eye, oral, mental, and cardiovascular health. The LIVE Dx platform enables population-scale screening with tele-health integration. Clinics 2.0 offers EHR, HIS, and practice management tools.

What the Numbers Show

The presentation highlights a vertically integrated model. The company controls the stack from proprietary magnet technology in hardware to AI analytics in software. This structure aims to create a single patient record across device, data, and decision layers.

Fischer Medical Ventures outlined its strategic expansion across radiology, preventive healthcare, and wellness solutions in a shareholder letter dated September 16, 2026. The company highlighted international deployments in Indonesia and the Philippines alongside a significant capital infusion by its promoter group.

The promoter group converted warrants and subscribed to a preferential allotment, injecting approximately ₹59.67 crore into the company. This transaction increased promoter shareholding from 62.15% to 63.08%. Fischer Medical Ventures organized its business into three segments: Radiology, Preventive Healthcare, and Wellness Solutions. The Radiology segment remains the largest, featuring proprietary imaging technology developed in-house over 15 years.

International Expansion

Fischer Medical Ventures entered the Indonesian market in October 2024 with its 4T4TB solution for tuberculosis detection. This integrated workflow combines portable digital X-ray systems with AI-assisted image analysis and the FMV Prime qPCR platform. The initiative supports Indonesia’s National Stop Tuberculosis Programme, which targets elimination by 2030. In the Philippines, subsidiary Time Medical Philippines Inc. installed its first open MRI at Bulacan Medical Centre in November 2025. The facility uses the PICA Open MRI system, chosen for its helium-free design and teleradiology capabilities.

Preventive Healthcare and Wellness

Through wholly owned subsidiary FlynnCare, the company offers AI-enabled screening via MIDAS kiosks and the LIVE Dx tele-diagnosis platform. A province-wide deployment in Catanduanes integrates Health Kiosks with the PhilHealth-accredited FlynnCare Clinical Management System. The Wellness Solutions segment plans to launch AI-powered Integrated Rehabilitation Centers in Malaysia, aiming for 20 centers over two years. Additionally, Fischer Medical Ventures strengthened its collaboration to bring Vecura, an AI-enabled molecular research platform, to India to support drug discovery.

What the Numbers Show

The promoter capital infusion of ₹59.67 crore resulted in a modest increase in holding from 62.15% to 63.08%. This suggests the primary objective was strengthening the balance sheet rather than significant equity dilution or control consolidation. The simultaneous rollout of hardware in Southeast Asia and software-led screening models indicates a strategic pivot toward diversified revenue streams beyond traditional imaging sales.